CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published research findings and current guideline recommendations on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and counsel patients about the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options for patients.
  • Explore available data with treatment intensification using cytotoxic and/or secondary hormonal therapy for metastatic hormone-sensitive prostate cancer, and effectively integrate these approaches into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available options for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess available research supporting the use of PARP inhibitors alone or with secondary hormonal therapies for patients with mCRPC, and discern how to optimally incorporate these agents into current and future treatment plans.
  • Appreciate available Phase III data leading to the recent FDA approval of PSMA-targeted radioligand therapy for progressive PSMA-positive mCRPC, and consider the optimal integration of this strategy into clinical care.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and short post-test, enables the participant to earn up 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCO22Prostate/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Andrew J Armstrong, MD, ScM
  Professor of Medicine, Surgery, Pharmacology and Cancer Biology
  Director of Research
  Duke Cancer Institute Center for Prostate and Urologic Cancers
  Divisions of Medical Oncology and Urology
  Duke University
  Durham, North Carolina
  
  Advisory Committee: Advanced Accelerator Applications, Exelixis Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, FORMA Therapeutics, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc; Contracted Research (to Institution): Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, FORMA Therapeutics, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc.
  
  Alan H Bryce, MD
  Chair, Division of Hematology and Medical Oncology
  Chair, Genitourinary Disease Group
  Mayo Clinic
  Phoenix, Arizona
  
  No relevant conflicts of interest to disclose.
  
  Alicia K Morgans, MD, MPH
  Genitourinary Medical Oncologist
  Medical Director, Survivorship Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Gilead Sciences Inc, MyovantSciences; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, Lantheus, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme, Telix Pharmaceuticals; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Myovant Sciences, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, and Sanofi Genzyme.
  
  Release date: June 2022
  Expiration date: June 2023
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.